COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D04DTH
|
|||
Drug Name |
Emapalumab
|
|||
Synonyms |
emapalumab; Gamifant; emapalumab-lzsg; GTPL9295; Ni-0501; NI0501
|
|||
Drug Type |
Monoclonal antibody
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2/3 | [1] | |
Other Indication | Primary haemophagocytic lymphohistiocytosis | Approved | [2] | |
Therapeutic Class |
Antiviral Agents
|
|||
PubChem Substance ID |
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN interferon gamma (IFNG) | Target Info | Inhibitor | [3], [4] |
Emapalumab is a humanized antibody targeting interferon gamma, which is elevated in COVID-19 and is responsible for the lethal complications such as cytokine release syndrome of COVID-19. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04324021) Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.. U.S. National Institutes of Health. | |||
2 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 761107. | |||
3 | Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology. 2004 Nov 10;329(1):11-7. doi: 10.1016/j.virol.2004.08.011. | |||
4 | Sobi to initiate a clinical study to evaluate whether anakinra and emapalumab may relieve complications associated with severe COVID-19 disease |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.